Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF53.40 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.07B
Enterprise ValueCHF1.25B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Jul 23, 2026Next Dividend Ex-DateN/A
Dividend Yield3.09%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF130.00Price Target Upside32.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
Bulls Say, Bears Say
Bulls Say
Specialized Gastroenterology FocusA focused franchise in gastroenterology/endoscopy creates durable product expertise and market positioning. Specialized clinical know‑how and regulatory experience increase barriers to entry, support repeat clinical use, and foster long-term customer relationships with hospitals and specialists.
Partnering And Licensing Revenue ModelA mixed monetization model (direct sales plus licensing, milestones and royalties) provides structural diversification of revenue and optionality. Partner-funded development and milestone upside reduce sole reliance on internal commercialization and can smooth cash flow over time.
Conservative Balance Sheet / Low LeverageVery low leverage and substantial equity give the company financial flexibility to fund development, bridge temporary cash shortfalls, or pursue partnerships/M&A without urgent refinancing. This resilience matters during cyclical revenue and cash‑flow swings.
Bears Say
Sharp 2025 Revenue And Profitability DropA large, recent revenue and margin deterioration indicates revenue concentration or loss of one-time items. Such steep declines harm long-term planning, lower reinvestment capacity, and raise risk that prior high-margin performance was non-repeatable rather than sustainable.
Deteriorated Cash GenerationA swing to negative operating and free cash flow is a structural red flag: it forces reliance on the balance sheet or external financing to fund operations and development, reducing strategic flexibility and potentially increasing dilution or cost of capital over the medium term.
Inconsistent Historical ProfitabilityRecurring volatility across years signals underlying unpredictability in demand, pricing, or one-off items. Persistent inconsistency complicates long-range forecasting, investor confidence, and the ability to execute multi-year investment plans for product development or market expansion.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF53.40 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.07B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 23, 2026 which is in 2 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.185 by -CHF0.277.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.942 which represents an annual dividend yield of 3.09%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.185. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF130.00
▲(32.92% Upside)